Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
09 Julio 2024 - 12:00AM
Vivoryon Therapeutics N.V. to Host
R&D Update Call on July 18, 2024 Focused on Progress in Kidney
Disease
Halle (Saale) / Munich, Germany,
July 9, 2024 - Vivoryon Therapeutics N.V.
(Euronext Amsterdam: VVY; NL00150002Q7)
(Vivoryon), a clinical stage company focused on
the discovery and development of small molecule medicines to
modulate the activity and stability of pathologically altered
proteins, today announced that it will host an R&D update
conference call and webcast on Thursday, July 18, 2024.
The call/webcast will include a presentation
from management discussing further analyses and data on
varoglutamstat’s observed beneficial effect on kidney function, an
update on the Company’s anticipated clinical development plan for
varoglutamstat in kidney disease and an opportunity for investor
and analyst questions.
Conference call detailsDate: July 18, 2024Time:
3:00 pm CEST / 9:00 am EDT The call is expected to last
approximately 60 minutes and will be available via phone and
webcast.
The live audio webcast of the call will be available on
Vivoryon´s website at:
https://www.vivoryon.com/news-and-events/presentations-webcasts/ A
replay of the webcast will also be available on the Company’s
website following the presentation.
To join the conference call via phone, participants may
pre-register and will receive dedicated dial-in details to easily
and quickly access the call via the following website:
https://register.vevent.com/register/BI3f611b5b7efe42389221ad3f4906aca8
It is suggested participants dial into the conference call 15
minutes prior to the scheduled start time to avoid any delays in
attendance.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology
company focused on developing innovative small molecule-based
medicines. Driven by its passion for ground-breaking science and
innovation, the Company strives to change the lives of patients in
need suffering from severe diseases. The Company leverages its
in-depth expertise in understanding post-translational
modifications to develop medicines that modulate the activity and
stability of proteins which are altered in disease settings. The
Company has established a pipeline of orally available small
molecule inhibitors for various indications including Alzheimer’s
disease, inflammatory and fibrotic disorders, including of the
kidney, and cancer. www.vivoryon.com.
Vivoryon Forward Looking Statements
This press release includes forward-looking
statements, including, without limitation, those regarding the
business strategy, management plans and objectives for future
operations of Vivoryon Therapeutics N.V. (the “Company”), estimates
and projections with respect to the market for the Company’s
products and forecasts and statements as to when the Company’s
products may be available. Words such as “anticipate,” “believe,”
“estimate,” “expect,” “forecast,” “intend,” “may,” “plan,”
“project,” “predict,” “should” and “will” and similar expressions
as they relate to the Company are intended to identify such
forward-looking statements. These forward-looking statements are
not guarantees of future performance; rather they are based on the
Management’s current expectations and assumptions about future
events and trends, the economy and other future conditions. The
forward-looking statements involve a number of known and unknown
risks and uncertainties. These risks and uncertainties and other
factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. The Company’s
results of operations, cash needs, financial condition, liquidity,
prospects, future transactions, strategies or events may differ
materially from those expressed or implied in such forward-looking
statements and from expectations. As a result, no undue reliance
should be placed on such forward-looking statements. This press
release does not contain risk factors. Certain risk factors that
may affect the Company’s future financial results are discussed in
the published annual financial statements of the Company. This
press release, including any forward-looking statements, speaks
only as of the date of this press release. The Company does not
assume any obligation to update any information or forward-looking
statements contained herein, save for any information required to
be disclosed by law.
For more information, please contact:
Investor ContactVivoryon Therapeutics N.V.Dr.
Manuela Bader, Director IR & CommunicationTel: +49 (0)345 555
99 30Email: IR@vivoryon.com
Media ContactTrophic CommunicationsValeria
FisherTel: +49 175 8041816Email: vivoryon@trophic.eu
- 20240709_VVY_July Webcast
Vivoryon Therapeut (EU:VVY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Vivoryon Therapeut (EU:VVY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
